Sexual Desire Support
FDA-approved bremelanotide may help treat acquired, generalized HSDD in eligible premenopausal women.
Injectable bremelanotide treatment with licensed provider oversight and an individualized care plan.
Program PricingPricing shown for information only. Your plan is confirmed after your free consultation.
Start Your JourneyPrescription products require an online consultation with a licensed healthcare provider who will determine whether treatment is appropriate.
PT-141, also known as bremelanotide, is a melanocortin receptor agonist used in sexual health treatment. FDA-approved bremelanotide is indicated for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Other uses may be considered off-label after individualized medical evaluation.
FDA-approved bremelanotide may help treat acquired, generalized HSDD in eligible premenopausal women.
Acts on melanocortin receptors rather than primarily targeting blood flow or hormone levels.
Bremelanotide is used as needed rather than as a daily medication when prescribed according to the FDA-approved regimen.
Treatment is based on symptoms, cardiovascular health, medications, medical history, and individual risks.
Low sexual desire and sexual dysfunction can have hormonal, psychological, neurological, medication-related, cardiovascular, and other causes.
FDA-approved bremelanotide is indicated for acquired, generalized HSDD that causes marked distress or interpersonal difficulty.
Symptoms may warrant evaluation to determine the underlying cause and appropriate treatment.
Bremelanotide use in men, including for erectile dysfunction or low sexual desire, is off-label and requires individualized evaluation.
Treatment requires review of cardiovascular health, medications, symptoms, and potential contraindications.
Bremelanotide is not FDA-approved to enhance sexual performance. A licensed healthcare provider will evaluate your symptoms, medical history, medications, cardiovascular health, and individual risks before recommending treatment.
Bremelanotide activates melanocortin receptors in the central nervous system. The exact mechanism by which it improves symptoms of HSDD is not fully understood. Treatment is individualized based on diagnosis, medical history, response, and potential risks.
PT-141 may cause side effects, and individual experiences can vary.
Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. It may also reduce exposure to orally administered naltrexone and affect absorption of certain other oral medications. Your provider will review your cardiovascular history, medications, and other risk factors before treatment.
Share your medical history, current symptoms, medications, cardiovascular history, and sexual wellness concerns through our secure online assessment.
Meet remotely with a licensed healthcare provider who will review your information and determine whether PT-141 or another treatment may be appropriate.
If treatment is prescribed, your medication and care plan will be coordinated through the appropriate licensed pharmacy, with administration instructions and ongoing provider oversight.
Discover other provider-guided treatments available through Premier Hormone Health.
Personalized hormone therapy guided by experienced providers.
Physician-guided plans for sustainable body composition improvement.
Provider-guided treatment options based on individual health needs.
PT-141 may be obtained online with a valid prescription after evaluation by a licensed healthcare provider. Avoid sources offering injectable peptides for self-treatment without appropriate medical and pharmacy oversight.
A PT-141 prescription online begins with a telehealth evaluation. Your provider reviews your symptoms, medical history, medications, cardiovascular health, and potential risks before determining whether treatment is appropriate.
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized HSDD in certain premenopausal women. Use in men, postmenopausal women, erectile dysfunction, or other sexual-health conditions is off-label.
Bremelanotide is FDA-approved as Vyleesi 1.75 mg/0.3 mL subcutaneous injection for certain premenopausal women with acquired, generalized HSDD. Compounded PT-141 formulations are not FDA-approved.
A provider may consider bremelanotide off-label for certain men after individualized evaluation, but FDA-approved Vyleesi is not indicated for men or for erectile dysfunction.